Life Sciences Tools and Services

ClinPlus

ClinPlus released FY2025 annual earnings on April 28 After-Market (BJT), actual revenue CNY 842.5 M (forecast CNY 865 M), actual EPS CNY 1.38 (forecast CNY 1.38)

ClinPlus released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 194.03 M, actual EPS CNY 0.15

ClinPlus released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 233.49 M, actual EPS CNY 0.2726

ClinPlus to Release FY2026 Q1 Earnings on April 29 After-Market BJT

ClinPlus to release FY2025 earnings on April 29 After-Market (BJT), forecast revenue CNY 865 M, EPS CNY 1.38

ClinPlus released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 218.91 M, actual EPS CNY 0.4195

ClinPlus released FY2025 9 Months Earnings on October 29 After-Market (BJT), with actual revenue of CNY 609.01 M and EPS of CNY 1.1375

ClinPlus FY2025 Q3 Earnings Release on October 30 After-Market BJT

ClinPlus released FY2025 Semi-Annual Earnings on August 28 During-Market (BJT), Actual Revenue CNY 390.1 M, Actual EPS CNY 0.69

ClinPlus released FY2025 Q2 earnings on August 28 During-Market (BJT), actual revenue CNY 213.63 M, actual EPS CNY 0.628

ClinPlus to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Lai Chunbao Completed Share 增持 of Pruis

Prisum Secretary Responds to Investor Inquiries about Business Cooperation

Pursys Sees Significant Growth in Quotation and New Orders in Q1 2025

ClinPlus released FY2024 Annual Earnings on April 28 After-Market (BJT), actual revenue CNY 803.73 M (forecast CNY 816 M), actual EPS CNY 1.35 (forecast CNY 1.34)

ClinPlus released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 176.47 M, actual EPS CNY 0.09

ClinPlus released FY2024 Q4 earnings on April 28 After-Market (BJT) with actual revenue of CNY 210.07 M and EPS of CNY 0.2933

ClinPlus FY2025 Q1 Earnings Release on April 29 After-Market BJT

ClinPlus to Release FY2024 Earnings on April 29 After-Market (BJT), Forecast Revenue CNY 816 M, EPS CNY 1.34

Lai Chunbao Increases Holdings in PuRuiSi Shares

301257

GLP's $1 billion bond maturing in 2028 plummeted 20% this week, marking the largest weekly decline, falling to 75 cents. Its two batches of perpetual notes also recorded the largest drop since 2022, falling to about 45 cents, now comparable to distressed bonds. Rumors suggest that Chinese financial regulators are guiding insurance companies to limit transactions with GLP, but GLP stated that it has not received any related notifications. This sell-off reflects market unease regarding GLP's upcoming IPO, indicating increased difficulty in IPO subscriptions against the backdrop of a fragile recovery in the Chinese market

Zaobao

Prologis bonds plummet this week, perpetual notes fall to distressed bond price levels | Lianhe Zaobao

ClinPlus released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 609 million yuan, a year-on-year increase of 2.59%. The net profit attributable to shareholders of the listed company was 87.3815 million yuan, a year-on-year increase of 20.92%. The net profit after deducting non-recurring gains and losses was 69.6744 million yuan, a year-on-year increase of 11.48%. The basic earnings per share were 1.11 yuan

Zhitong

ClinPlus released its performance for the first three quarters, with a net profit attributable to the parent company of 87.3815 million yuan, an increase of 20.92%

688320

000410

688152

300351

On October 28th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approximately 6.034 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlock Shares Shen Machine 000410 Additional A Shares Legal Person Allocation Listed 381 million Yonggui Electric 300351 Equity Incentive Restricted Circulation 451,400 ClinPlus 301257 Equity Incentive Restricted Circulation 292,500 HCFA 688320 4,013,700 Hunan Kylinsec Technology 688152 4,768,000

HCFA

SMTCL

Hunan Kylinsec Technology

Yonggui

Zhitong A-share lock-up release overview | October 28

According to the Zhitong Finance APP, ClinPlus announced that its shareholder Shanghai Guanyu Investment Development Co., Ltd. Guanyu Zhaotai (Jiaxing) Venture Capital Partnership (Limited Partnership) (hereinafter referred to as "Guanyu Zhaotai") plans to reduce its holdings of the company's shares by no more than 2.3701 million shares (accounting for 3.00% of the company's total share capital) through centralized bidding and/or block trading within three months after 15 trading days from the date of this announcement

ClinPlus shareholders view Zhao Tai intends to reduce its holdings by no more than 3%

603127

06127

300584

002821

06821

The innovative drug concept has seen a surge in activity. As of the time of writing, JOINN has hit the daily limit, with ClinPlus, Hicin Pharmaceutical, Asymchem, and others following suit

JOINN

Hicin Pharmaceutical

Asymchem

Innovative drug concept experiences a surge, JOINN hits the daily limit up

According to the Zhitong Finance APP, ClinPlus released its semi-annual report for 2025, showing an operating income of 390 million yuan, a year-on-year decrease of 1.08%. The net profit attributable to shareholders of the listed company was 54.1561 million yuan, a year-on-year decrease of 1.40%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 38.5445 million yuan, a year-on-year decrease of 20.35%. The basic earnings per share were 0.69 yuan

ClinPlus released its performance for the first half of the year, with a net profit attributable to the parent company of 54.1561 million yuan, a decrease of 1.40%

300683

The innovative drug concept fluctuated and rebounded during the day, with ClinPlus and HITECK rising over 10%. Previously, Nanjing Xinbai and Saili Medical hit the daily limit, while Mediso and Boteng Co., Ltd., Zhaoyan New Drug, Kanglong Huacheng, and Borui Pharmaceutical rose over 5%

HITECK

The concept of innovative drugs fluctuates and rebounds, HITECK and ClinPlus rise over 10%

000989

688136

600276

688202

Innovative drug concept stocks rebound after hitting bottom, JZT reaches the daily limit, ClinPlus rises over 10%, Medicilon, SDKX, and Hengrui Pharma all rise

SDKX

Hengrui Pharma

Medicilon

Innovative drug concept stocks rebound after hitting bottom, JZT reaches the daily limit

603716

688553

The innovative drug concept fluctuated and rebounded during the day, with the CXO sector leading the gains. ClinPlus rose over 10%, while Medicilon, JZT, Thalys, HUIYU PHARMACEUTICAL, and Shanghai Yizhong all rose over 6%

Thalys

HUIYU PHARMACEUTICAL

The concept of innovative drugs fluctuates and rebounds, ClinPlus rises over 10%

According to the Qichacha APP, recently, Rongxin Zhiyan Pharmaceutical Technology Co., Ltd. was established, with Wei Li as the legal representative. The business scope includes: medical research and experimental development; second-class value-added telecommunications services, etc. Qichacha's equity penetration shows that the company is wholly owned by ClinPlus

ClinPlus has established a new pharmaceutical technology company in Chengdu

ClinPlus(301257.SZ)